Cameron Wolfe is an Infectious Disease physician affiliated with Duke University. OpenAlex indexes 191 publications with 7,615 citations (h-index 34); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2100 Erwin Rd
Durham, NC 277100001
Telephone
919-970-3885Registry record last updated 17 Jul 2008.
Clinical trials
- Transplantation and the Use of Raltegravir in HIV-Infected Patients
Sponsor: Duke University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202513 payments$19,386openpaymentsdata.cms.gov ↗
- CSL BehringProgram year20254 payments$18,600openpaymentsdata.cms.gov ↗
- Janssen Research & Development, LLCProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
64.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor20%Dovato42%Tivicay31%Juluca20%Isentress7%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor15.8%Triumeq88%Abacavir-Lamivudine12%Part D<11 patients+ 8 more classes in this area
Cardiovascular
12.3%Statin5.6%Pravastatin Sodium61%Atorvastatin Calcium40%Part D<11 patientsACE inhibitor4.7%Lisinopril100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
9.6%GLP-1 receptor agonist5.5%Mounjaro60%Ozempic41%Part D<11 patientsProton pump inhibitor4.1%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients
Open Forum Infectious Diseases
2024 - Severe Monkeypox in Hospitalized Patients — United States, August 10–October 10, 2022
MMWR Morbidity and Mortality Weekly Report
2022 - Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
The Lancet Respiratory Medicine
2022 - Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases
The Journal of Heart and Lung Transplantation
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”